Previous 10 | Next 10 |
CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics , a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will ...
Extensive Analyses in Multiple Human Cell Types Demonstrate Minimal to No Off-target Editing Following VERVE-101 Treatment, Supporting its Planned Clinical Initiation in 2022 Whole Genome Sequencing at 500X Coverage of Primary Human Liver Cells Treated with VERVE-101 Demonstrate...
Verve Therapeutics is a biotechnology company with a vision to provide cutting-edge solutions to cardiovascular diseases. The company is dedicated to creating genetic therapies to confer protection against coronary diseases. Verve Therapeutics provides a new therapeutic approach w...
Updated Sequential Dosing Data Show Administration of PCSK9 Base Editor Followed by ANGPTL3 Base Editor is Well-Tolerated in NHPs Data to be Presented Today at the American College of Cardiology 71 st Annual Scientific Session & Expo CAMBRIDGE, Mass., April 0...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
CAMBRIDGE, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics , a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Andrew Bellinger, M.D., Ph.D., chief scientific officer and c...
Gainers: Incannex Healthcare IXHL +209%. Revelation Biosciences (NASDAQ:REVB) +25%. Co-Diagnostics CODX +14%. GreenLight Biosciences (NASDAQ:GRNA) +14%. Clearside Biomedical (NASDAQ:CLSD) +12%. Losers: Better Therapeutics BTTX -33%. ANI Pharmaceuticals ...
Verve Therapeutics press release (NASDAQ:VERV): Q4 GAAP EPS of -$0.65 misses by $0.12. Cash, Cash Equivalents and Marketable Securities of $360.4 Million with Cash Runway into 2024 For further details see: Verve Therapeutics GAAP EPS of -$0.65 misses by $0.12
Significant Progress Anticipated in 2022 with Initiation of Clinical Trial for VERVE-101 and IND-enabling Studies for ANGPTL3 Program Presentations at Upcoming Scientific Conferences to Highlight Novel Base Editing Approach and Proprietary Lipid Nanoparticle Delivery System ...
CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics , a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...